相关实验视频
Updated: Jun 4, 2025

Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
作为高度强大的KPC抑制剂的2-碳氧基诺林酸
Zheng Ma1, Ge Cui1, Lijie Dou1
1State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, Frontiers Science Center for Materiobiology and Dynamic Chemistry, Shanghai Frontier Science Research Base of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, P.R. China.
研究人员发现了新型的2 - 碳基诺林玻酸,可以抑制Klebsiella pneumoniae carbapenemase (KPC). 化合物1e有效地对抗KPC-2耐药性,恢复抗生素对抗耐药性Klebsiella pneumoniae的疗效.
科学领域:
- 药用化学 医学化学
- 微生物学 微生物学
- 药物发现 药物发现 药物发现
背景情况:
- 克莱布西拉肺炎卡巴胺酶 (KPC) 赋予了对卡巴胺的耐药性,这是关键的最后手段抗生素.
- 抗微生物耐药性不断增加,需要针对格拉姆阴性细菌感染的新型治疗策略.
研究的目的:
- 发现和描述KPC的新型抑制剂.
- 评估这些抑制剂在恢复抗生素对耐药细菌的疗效方面的潜力.
主要方法:
- 合成和选的2-碳基诺林玻酸衍生物.
- 对KPC-2和其他β-乳酸酶的酶抑制试验 (IC50测定)
- 细胞毒性,血液溶解和抗菌活性评估.
- 在实验室中增强β-乳糖抗生素对抗耐药的Klebsiella pneumoniae.
主要成果:
- 化物替代的碳氧基诺林酸1e成为一种强大的KPC-2抑制剂 (IC50 = 8.3 nM).
- 化合物1e表现出选择性,对其他β-乳酸酶的活性降低.
- 低细胞毒性,血液溶解和内在抗菌活性被观察到1e.
- 化合物1e显著增强了美罗和塞夫塔齐迪姆对表达KPC-2的Klebsiella肺炎的疗效 (高达256倍).
结论:
- 2 - 碳基诺林玻酸代表了一个有前途的类型的KPC抑制剂.
- 化合物1e显示出作为一种辅助疗法的潜力,以克服卡巴胺耐药性.
- 进一步的开发可能会导致新的治疗KPC产生的细菌引起的感染.
相关概念视频
Inhibition of Cdk Activity
Gene Regulation in Microbial Communities: Quorum Sensing
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Cofactors and Coenzymes
Carbocations

